u/Emotional-Breath-838

The author claims Alpha Tau's DaRTS local alpha radiation repeatedly demonstrates systemic elimination of tumors unassociated with the treated area, retraining the immune system against solid tumors. This mechanism, the author argues, could make DaRTS a first-line treatment for all solid tumors, expanding the addressable market far beyond the hardest-to-treat cases and justifying adding a zero to the current roughly $600M valuation toward a $5B-plus figure. The catalyst cited is the JPM26 presentation and Cathie Wood placing the first institutional order.

The author claims Tesla is one of a very small handful of companies whose corporate development teams are sharp enough to win the majority of their risk-taking bets, keeping the company out in front of the herd. This innovation leadership is expected to produce outsized returns over time compared with slower-growing companies. The stated reasoning is that the company takes calculated risks in innovation and has strong deal-making capability.